AstraZeneca on Tuesday released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease, boosting hopes that it could generate multibillion-dollar sales for the company. The biologic medicine, tozorakimab, is under priority review by the Food and Drug Administration, with U.S. approval expected in the first quarter of 2027….
Eli Lilly and Regeneron are among the first seven companies the U.S. Food and Drug Administration selected for a pilot program designed to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC has learned. Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA’s…
Regeneron Pharmaceuticals will make its newly approved gene therapy for a rare, genetic form of hearing loss available for free in the U.S. The company hasn’t yet decided how much it will charge in other countries, Regeneron CEO Leonard Schleifer told CNBC on Friday. “We haven’t set a price yet, but they should pay their…
U.S. President Donald Trump (C) speaks during an event on advancing health care affordability in the Oval Office of the White House on April 23, 2026 in Washington, DC. Alex Wong | Getty Images Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump, the White…
The Trump administration on Thursday imposed new tariffs on branded drugs from pharmaceutical companies that have not struck deals with the president to lower their U.S. drug prices – a long-awaited move that will likely only affect a small portion of drugmakers. “We need to make sure that our drug supply is protected, secure and…
AstraZeneca‘s stock rose over 3% after Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease (COPD) in both former smokers and in the overall population versus placebo, the company said. “This marks a notable shift…
Last summer, my sister Becky approached me with an idea. She wanted my help building a platform at CNBC to spotlight the 30 million Americans living with a rare disease. Becky hoped that doing so would help give a voice to the millions of people that are often overlooked by the medical community … who…
The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the…
We get so caught up in the buzz and the sizzle that we forget about the steak, especially in this era of GLP-1s, which have revolutionized the treatment of diabetes and obesity and are being studied for so many more diseases and conditions. That’s my chief takeaway from meeting with 15 different CEOs, a dozen…
Every weekday, the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. 1. The S & P 500 was basically flat Wednesday after a record high in the prior session. Oil prices were down on expectations of more crude supply from Venezuela….
